Bioequivalence Study of Escitalopram Tablets 10 mg
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this study was to confirm if two formulations of escitalopram tablets are bioequivalent.
Test product was escitalopram (10 mg; GlaxoSmithKline) and reference product Lexapro® (10 mg escitalopram; Lundbeck). The single dosage was one tablet.
The study was prospective, open-label, randomized, crossover, single dose, with 02 treatments, 02 sequences and 02 periods, under fasting conditions.
The population was composed of 26 healthy volunteers, male adults between 18-50 years.
The comparative bioavailability of the two formulations was evaluated based in statistical comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations in blood.
| Condition | Intervention | Phase |
|---|---|---|
|
Anxiety Disorders |
Drug: escitalopram 10 mg |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Crossover Assignment Masking: Open Label |
| Official Title: | Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparations in Tablets Containing Escitalopram 10 mg (Product From GlaxoSmithKline México, S.A. de C.V. vs. Lexapro® 10mg, Lundbeck México, S.A. de C.V.) in Fasting Healthy Volunteers |
- Peak Plasma Concentration (CMAX) of escitalopram [ Time Frame: 0.0, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 18.0, 22.0, 48.0, 72.0, and 96.0 postdosage ] [ Designated as safety issue: No ]Pharmacokinetics
- Area under the plasma concentration versus time curve (AUC) of escitalopram [ Time Frame: 0.0, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 18.0, 22.0, 48.0, 72.0, and 96.0 postdosage ] [ Designated as safety issue: No ]Pharamacokinetics
| Enrollment: | 26 |
| Study Start Date: | May 2010 |
| Study Completion Date: | May 2010 |
| Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: A(reference)/B(test)
initial administration of reference and cross-over to test
|
Drug: escitalopram 10 mg
Reference product
Other Name: Lexapro® LUNDBECK MEXICO SA de CV
Drug: escitalopram 10 mg
Test product
Other Name: escitalopram GLAXOSMITHKLINE MEXICO SA de CV
|
|
Experimental: B(test)/A(reference)
initial administration of test and cross-over to reference
|
Drug: escitalopram 10 mg
Reference product
Other Name: Lexapro® LUNDBECK MEXICO SA de CV
Drug: escitalopram 10 mg
Test product
Other Name: escitalopram GLAXOSMITHKLINE MEXICO SA de CV
|
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Free will participation according to Mexican regulation, Helsinki Declaration, and Good Clinical Practice.
Males between 18 and 50 years. Body Mass Index between 18 and 27.5 In good health by complete medical history and laboratory tests. Blood pressure 130-90/ 90-60 mm Hg; heart rate 55-100 beat per minute, respiratory rate 14-20 movements per minute.
Laboratory tests +/- 10% of normal interval (blood cytology, blood chemistry 27 elements, Hepatitis B and C antigens, HIV, urinalysis, anti-doping, pregnancy, electrocardiogram)
Exclusion Criteria:
Alteration of vital signs Not complying with inclusion criteria History of cardiovascular, kidney, hepatic, muscular, metabolic, gastrointestinal (including constipation), neurologic, endocrine, hematopoietic (any kind of anemia), asthma, mental or organic disease. Those suffering from muscular trauma 21 days before the beginning of the study.
Requirement of any kind of medication during the course of the study, except study medication.
History of dyspepsia, gastritis, esophagitis, duodenal or gastric ulcer. Exposure to medications known as inducers or inhibitors of hepatic enzymes or administration of potentially toxic medication in the 30 days before the study beginning.
Administration of any medication in the 14 days or 5 half-lives (whatever longer) previous to the beginning of the study.
Hospitalization for any cause in the seven months before the beginning of the study.
Administration of investigational drugs in the 60 days before the study. Allergy to any medication, substance, or food. Alcohol ingestion or intake of beverages containing xanthines (coffee, tea, cocoa, chocolate, mate, cola drinks) or ingestion of charcoal grilled food or grapefruit or orange juice in the 72 hours before the hospitalization or tobacco smoking in the 72 hours before the beginning of the study.
Blood donation or loss => 450 ml in the 60 days before the beginning of the study.
History of drug or alcohol abuse. Special diet requirement, for instance vegetarian diet. Inability to understand nature, aims, and possible consequences of the study. Evidence of non-cooperative attitude during the study.
Contacts and Locations More Information
No publications provided
| Responsible Party: | GlaxoSmithKline |
| ClinicalTrials.gov Identifier: | NCT01745601 History of Changes |
| Other Study ID Numbers: | 117003 |
| Study First Received: | December 6, 2012 |
| Last Updated: | December 6, 2012 |
| Health Authority: | Mexico: Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS) |
Additional relevant MeSH terms:
|
Anxiety Disorders Mental Disorders Dexetimide Citalopram Antiparkinson Agents Anti-Dyskinesia Agents Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Parasympatholytics Autonomic Agents Peripheral Nervous System Agents |
Physiological Effects of Drugs Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Serotonin Agents |
ClinicalTrials.gov processed this record on May 21, 2013